Skip to main content
Log in

Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Oral anticoagugulants (OACs) effectively reduce the risk for ischemic stroke in patients with atrial fibrillation (AF), but undertreatment and poor persistence with treatment are important problems. NOACs now provide alternatives to warfarin. This study compares the persistence with presently available antithrombotic treatments in AF patients with a CHA2DS2VASc score ≥2.

Methods

All first claims of either warfarin (n = 9969), dabigatran (n = 2701), rivaroxaban (n = 2074), apixaban (n = 1352), or aspirin (n = 4540) from April 2011 until December 2014, in individuals with non-valvular AF and CHA2DS2VASc scores of 2–9, were identified in the administrative health data register (VAL) of the Stockholm region (2.1 million inhabitants). Prescription claims were analyzed with and without multivariate analysis in relation to age, sex, prescriber category, prior OAC treatment, number of drugs, and death.

Results

The overall persistence with any OAC was 88.2 % (CI 87.5–88.9) at 1 year and 82.9 % (CI 81.8–83.9) at 2 years. After 1 year, the crude persistence was 85.0 % (CI 84.2–85.9) with warfarin, 85.9 % (CI 81.8–90.1) with apixaban, 74.4 % (CI 72.3–76.5) with dabigatran, and 77.4 % (CI 74.6–80.2) with rivaroxaban. Multivariate analysis confirmed significantly higher persistence with warfarin and apixaban than with dabigatran or rivaroxaban. The adherence (proportion of days covered >80 %) was above 90 % for all NOACs; significantly higher with rivaroxaban compared to dabigatran (p < 0.001), but not compared to apixaban (p = 0.14).

Conclusions

After 2 years, the persistence with any anticoagulant treatment was high in patients with non-valvular AF. Our results indicate better persistence with warfarin and apixaban than with dabigatran or rivaroxaban in regular care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Friberg L, Bergfeldt L (2013) Atrial fibrillation prevalence revisited. Intern Med 274:461–468

    Article  CAS  Google Scholar 

  2. Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P (2014) Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol 70:1477–1485

    Article  CAS  PubMed  Google Scholar 

  3. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867

    Article  PubMed  Google Scholar 

  4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. (2009) (For the RE-LY investigators): dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  CAS  PubMed  Google Scholar 

  5. Patel MR, Mahaffey KW, Garg J, et al. (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 8(365):883–891

    Article  Google Scholar 

  6. Granger CB, Alexander JH, McMurray JJ, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992

    Article  CAS  PubMed  Google Scholar 

  7. Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P (2013) Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. Int J Cardiol 170:208–214

    Article  PubMed  Google Scholar 

  8. Camm AJ, Lip GY (2012) De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG); 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747

    Article  PubMed  Google Scholar 

  9. Chatterjee S, Sardar P, Giri JS, Ghosh J, Mukherjee D (2014) Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc 89:896–907

    Article  PubMed  Google Scholar 

  10. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817

    Article  Google Scholar 

  11. Eichler HG, Abadie E, Breckenridge A, et al. (2011) Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Review Drug Discov. 10:495–506

    Article  CAS  Google Scholar 

  12. Skeppholm M, Friberg L (2014) Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol 103:998–1005

    Article  CAS  PubMed  Google Scholar 

  13. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G (2014) Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 35:3365–3376

    Article  PubMed  Google Scholar 

  14. Song X, Sander SD, Varker H, Amin A (2012) Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs 12:245–253

    PubMed  Google Scholar 

  15. Gallagher AM, Rietbrock S, Plumb J, van Staa TP (2008) Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 6:1500–1506

    Article  CAS  PubMed  Google Scholar 

  16. Suh DC, Choi JC, Schein J, Kim S, Nelson WW (2013) Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients. Curr Med Res Opin 29:761–771

    Article  PubMed  Google Scholar 

  17. Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H (2013) Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 6:567–574

    Article  PubMed  Google Scholar 

  18. Beyer-Westendorf J, Ebertz F, Förster K, Gelbricht V, Michalski F, Köhler C, Werth S, Endig H, Pannach S, Tittl L, Sahin K, Daschkow K, Weiss N (2015) Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC registry. Thromb Haemost 113:1247–1257

    Article  PubMed  Google Scholar 

  19. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, Bradley SM, Maddox TM, Grunwald GK, Barón AE, Rumsfeld JS, Varosy PD, Schneider PM, Marzec LN, Ho PM (2014) Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the Veterans health administration. Am Heart J 167:810–817

    Article  CAS  PubMed  Google Scholar 

  20. Shore S, Ho PM, Lambert-Kerzner A, Glorioso TJ, Carey EP, Cunningham F, Longo L, Jackevicius C, Rose A, Turakhia MP (2015) Site-level variation in and practices associated with dabigatran adherence. J Am Med Assoc 313:1443–1450

    Article  CAS  Google Scholar 

  21. Beyer-Westendorf J, Förster K, Ebertz F, Gelbricht V, Schreier T, Göbelt M, Michalski F, Endig H, Sahin K, Tittl L, Weiss N (2015) Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 17:530–538

    Article  PubMed Central  PubMed  Google Scholar 

  22. Nelson WW, Song X, Coleman CI, Thomson E, Smith DM, Damaraju CV, Schein JR (2014) Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 30:2461–2469

    Article  CAS  PubMed  Google Scholar 

  23. Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P (2014) Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 30:1317–1325

    Article  PubMed  Google Scholar 

  24. Caetano PA, Lam JM, Morgan SG (2006) Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 28:1411–1424

    Article  PubMed  Google Scholar 

  25. Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF (2013) Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 51:S11–S21

    Article  PubMed Central  PubMed  Google Scholar 

  26. Friberg L, Skeppholm M, Terént A (2015) Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 65:225–232

    Article  PubMed  Google Scholar 

  27. Wettermark B, Hammar N, Fored M, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M (2007) The new Swedish prescribed drug register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726–735

    Article  PubMed  Google Scholar 

  28. January CT, Wann LS, Alpert JS, Calkins H, Cleveland Jr JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circ 130:2071–2104

    Article  Google Scholar 

  29. Ben Freedman S, Gersh BJ, Lip GY (2015) Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. Eur Heart J 36:653–656

    Article  CAS  PubMed  Google Scholar 

  30. Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A (2015) Safety and efficacy of well managed warfarin. A report from the Swedish quality register auricula. Thromb Haemost 113:1370–1377

    Article  PubMed  Google Scholar 

  31. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM (2013) Fox KA; ROCKET AF investigators. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2:e000067

    PubMed Central  PubMed  Google Scholar 

  32. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC (2009) Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 15:e22–e33

    PubMed  Google Scholar 

  33. Vrijens B, Heidbuchel H (2015) Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 17:514–523

    Article  PubMed  Google Scholar 

  34. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450

    Article  PubMed Central  PubMed  Google Scholar 

  35. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA (2011) Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 90:777–790

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Per Näsman (PhD, Royal Institute of Technology, Stockholm, Sweden) for statistical advice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tomas Forslund.

Ethics declarations

Funding

Funding was provided from the Stockholm County Council.

Disclosures

None.

Electronic supplementary material

ESM 1

(DOCX 18 kb)

ESM 2

(DOCX 17 kb)

ESM 3

(DOCX 14 kb)

ESM 4

(DOCX 13 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Forslund, T., Wettermark, B. & Hjemdahl, P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol 72, 329–338 (2016). https://doi.org/10.1007/s00228-015-1983-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-015-1983-z

Keywords

Navigation